Overview

A Study to Assess the Safety and Efficacy of AZD2936 in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Status:
Recruiting
Trial end date:
2023-12-07
Target enrollment:
Participant gender:
Summary
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody, AZD2936 is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AstraZeneca